TY - JOUR
T1 - Quaternized starch-based carrier for siRNA delivery
T2 - From cellular uptake to gene silencing
AU - Amar-Lewis, Eliz
AU - Azagury, Aharon
AU - Chintakunta, Ramesh
AU - Goldbart, Riki
AU - Traitel, Tamar
AU - Prestwood, Jackson
AU - Landesman-Milo, Dalit
AU - Peer, Dan
AU - Kost, Joseph
N1 - Funding Information:
This work was supported by the Focal Technological Area Program of the Israel National Nanotechnology Initiative (INNI) (Bio-inspired Nano-carriers for Sub-Cellular Targeted Therapeutics). We wish to thank Roxana Golan (Ilse Katz Institute for Nanoscale Science and Technology) for the assistance in AFM imaging and Alon Zilha (National Institute for Biotechnology in the Negev Ltd.) for the assistance in flow cytometry analysis.
PY - 2014/7/10
Y1 - 2014/7/10
N2 - RNAi therapeutics is a powerful tool for treating diseases by sequence-specific targeting of genes using siRNA. Since its discovery, the need for a safe and efficient delivery system for siRNA has increased. Here, we have developed and characterized a delivery platform for siRNA based on the natural polysaccharide starch in an attempt to address unresolved delivery challenges of RNAi. Modified potato starch (Q-starch) was successfully obtained by substitution with quaternary reagent, providing Q-starch with cationic properties. The results indicate that Q-starch was able to bind siRNA by self-assembly formation of complexes. For efficient and potent gene silencing we monitored the physical characteristics of the formed nanoparticles at increasing N/P molar ratios. The minimum ratio for complete entrapment of siRNA was 2. The resulting complexes, which were characterized by a small diameter (~ 30 nm) and positive surface charge, were able to protect siRNA from enzymatic degradation. Q-starch/siRNA complexes efficiently induced P-glycoprotein (P-gp) gene silencing in the human ovarian adenocarcinoma cell line, NCI-ADR/Res (NAR), over expressing the targeted gene and presenting low toxicity. Additionally, Q-starch-based complexes showed high cellular uptake during a 24-hour study, which also suggested that intracellular siRNA delivery barriers governed the kinetics of siRNA transfection. In this study, we have devised a promising siRNA delivery vector based on a starch derivative for efficient and safe RNAi application.
AB - RNAi therapeutics is a powerful tool for treating diseases by sequence-specific targeting of genes using siRNA. Since its discovery, the need for a safe and efficient delivery system for siRNA has increased. Here, we have developed and characterized a delivery platform for siRNA based on the natural polysaccharide starch in an attempt to address unresolved delivery challenges of RNAi. Modified potato starch (Q-starch) was successfully obtained by substitution with quaternary reagent, providing Q-starch with cationic properties. The results indicate that Q-starch was able to bind siRNA by self-assembly formation of complexes. For efficient and potent gene silencing we monitored the physical characteristics of the formed nanoparticles at increasing N/P molar ratios. The minimum ratio for complete entrapment of siRNA was 2. The resulting complexes, which were characterized by a small diameter (~ 30 nm) and positive surface charge, were able to protect siRNA from enzymatic degradation. Q-starch/siRNA complexes efficiently induced P-glycoprotein (P-gp) gene silencing in the human ovarian adenocarcinoma cell line, NCI-ADR/Res (NAR), over expressing the targeted gene and presenting low toxicity. Additionally, Q-starch-based complexes showed high cellular uptake during a 24-hour study, which also suggested that intracellular siRNA delivery barriers governed the kinetics of siRNA transfection. In this study, we have devised a promising siRNA delivery vector based on a starch derivative for efficient and safe RNAi application.
KW - Drug delivery
KW - Polysaccharide
KW - Quaternized starch
KW - Self-assembly complexes
KW - Small interfering RNA
UR - http://www.scopus.com/inward/record.url?scp=84901817333&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2014.04.031
DO - 10.1016/j.jconrel.2014.04.031
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:84901817333
SN - 0168-3659
VL - 185
SP - 109
EP - 120
JO - Journal of Controlled Release
JF - Journal of Controlled Release
IS - 1
ER -